ArticleClinical and experimental nephrology2025
Gelsolin as a predictor of arteriovenous fistula maturation.
Article in Clinical and experimental nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Preoperative Serum Alkaline Phosphatase Predicts Arteriovenous Fistula Maturation Failure.Kidney international reports · 2026Article
- Sex-Specific Impact of Inflammation and Nutritional Indices on AVF Blood Flow and Maturation: A Retrospective Analysis.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGelsolin is a key regulator of actin filament metabolism and plays a role in tissue remodeling. We evaluated plasma gelsolin (pGSN) in predicting arteriovenous fistula (AVF) maturation.
methodsOnly patients with newly created radiocephalic AVF were included. pGSN and plasma F-actin levels were measured preoperatively. Maturation was defined as an access (cephalic) vein diameter > 5 mm and a fistula blood flow rate > 500 mL/min in ultrasound, 8 weeks after operation.
resultsA total of 68 patients were analyzed with a mean age of 62.6 ± 11.1 years. AVF maturation was identified in 39 patients (57.3%). Mean pGSN level was 4726 (3836-6483) ng/mL in patients with mature AVF and 3237 (2895-4382) ng/mL in patients with immature AVF. pGSN levels were significantly higher (p < 0.001) in the mature AVF group. F-actin levels were not significantly different between two groups. pGSN levels positively correlated with fistula blood flows (r = 0.326, p = 0.007). Multivariate logistic regression analysis revealed that pGSN (p = 0.003) was determined to be an independent risk factor in predicting AVF maturation. Preoperative pGSN levels were significantly predictive of AVF maturation in the ROC analysis. Sensitivity and specificity of pGSN were 82.1% and 58.6%, respectively, with a cut-off value of > 3716 ng/mL and an area under the ROC curve of 0.75 (95% CI: 0.64-0.87, p < 0.001).
conclusionCurrent results demonstrated that patients with mature AVFs had significantly higher preoperative pGSN levels compared to those with immature AVFs. Outcomes suggest that pGSN could serve as a predictive biomarker for AVF maturation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.